All News

In clinical trials, AbbVie's risankizumab-rzaa produced high rates of durable skin clearance – most people (82 and 81%) treated with the drug achieved 90% skin clearance (PASI 90) at 1 year, with the majority (56 and 60%) achieving complete skin clearance (PASI 100).